Phase I/II clinical trial of TZ 101-fucosylated regulatory T cells for prevention of graft versus host disease in patients eligible for haematologic stem cell transplant.

Trial Profile

Phase I/II clinical trial of TZ 101-fucosylated regulatory T cells for prevention of graft versus host disease in patients eligible for haematologic stem cell transplant.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jul 2016

At a glance

  • Drugs TZ 101 (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Targazyme
  • Most Recent Events

    • 20 Jul 2016 According to Targazyme media release, company has enrolled the first patient in this study.
    • 20 Jul 2016 Status changed from not yet recruiting to recruiting, as reported by Targazyme media release.
    • 27 Jul 2015 According to Targazyme media release, company received National Cancer Institute SBIR award as fund for conducting this study at The University of Texas MD Anderson Cancer Center and at the University of Minnesota.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top